New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:48 EDTLGND, ONXXLigand Pharma should benefit significantly from Onyx drug, says Roth Capital
After Onyx (ONXX) reported $18.6M in Kyprolis sales for Q3, Roth Capital notes that Ligand (LGND) receives a 3% average royalty on Kyprolis sales. The firm believes that Kyprolis will help enable Ligand to rapidly become profitable and it maintains a $25 target and Buy rating on the stock.
News For LGND;ONXX From The Last 14 Days
Check below for free stories on LGND;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:13 EDTLGNDLigand's partner Spectrum says Captisol-enabled melphalan meets primary endpoint
Subscribe for More Information
07:10 EDTLGNDSpectrum announces CE Melphalan trial met primary end points
Subscribe for More Information
April 21, 2014
06:49 EDTLGNDLigand May volatility elevated at 81
Subscribe for More Information
April 17, 2014
03:59 EDTLGNDLigand volatility at historic high
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use